This week, Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas around non-invasive testing. Mazen Noureddin joins co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to discuss serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF).
00:00 Return of Regular Podcast Scheduling
07:59 Introducing the Metabolomics-Advanced steatohepatitis fibrosis score (MASEF)
16:42 Cost Effectiveness and Application Settings
27:27 Next Steps and New Cohorts
35:36 MASEF: Where will we be in 2 years?
Mazen co-authored a paper on the subject which was published in Hepatology as recent as late July. In a nutshell, this episode elucidates on developing and validating a highly specific metabolomics-driven score to identify at-risk MASH (metabolic dysfunction-associated steatohepatitis) patients.
Ultimately, the paper concludes MASEF to indeed be a promising diagnostic tool for the assessment of at-risk MASH. Specifically, it states that MASEF “could be used alternatively to liver stiffness measurement by VCTE in the algorithm that is currently recommended by several guidance publications.” Listen to the Surfers respond with their thoughts, questions and varying perspectives.
If you have questions or comments around MASEF, metabolomics or any other ideas considered in this episode, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com. The Surfing the NASH Tsunami will be back next week with more original content.
Stay Safe and Surf On!
